{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:33:42Z","timestamp":1785170022865,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Research to Prevent Blindness, Inc","award":["P30 EY014801"],"award-info":[{"award-number":["P30 EY014801"]}]},{"name":"National Eye Institute, National Institutes of Health"},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["W81XWH-09\u20131-0675"],"award-info":[{"award-number":["W81XWH-09\u20131-0675"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.ajo.2011.11.023","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T18:23:22Z","timestamp":1326911002000},"page":"196-203.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Avastin Doesn't Blind People, People Blind People"],"prefix":"10.1016","volume":"153","author":[{"given":"Serafin","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajo.2011.11.023_bib1","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ajo.2011.11.035","article-title":"An outbreak of Streptococcus endophthalmitis after intravitreal injection of bevacizumab","volume":"153","author":"Goldberg","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2011.11.023_bib2","series-title":"FDA alerts health care professionals of infection risk from repackaged Avastin intravitreal injections","year":"2011"},{"key":"10.1016\/j.ajo.2011.11.023_bib3","series-title":"Doctors grow wary of Avastin for eye treatment","author":"Pollack","year":"2011"},{"key":"10.1016\/j.ajo.2011.11.023_bib4","series-title":"AAO update: VA reinstates use of Avastin","year":"2011"},{"issue":"5","key":"10.1016\/j.ajo.2011.11.023_bib5","doi-asserted-by":"crossref","first-page":"887e1","DOI":"10.1016\/j.ajo.2010.11.017","article-title":"Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service part B claims file","volume":"151","author":"Brechner","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"20","key":"10.1016\/j.ajo.2011.11.023_bib6","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2011.11.023_bib7","series-title":"Severe intraocular inflammation\/endophthalmitis following off-label treatment with intravitreal bevacizumab","year":"2009"},{"issue":"8","key":"10.1016\/j.ajo.2011.11.023_bib8","doi-asserted-by":"crossref","first-page":"e664","DOI":"10.1111\/j.1755-3768.2010.02054.x","article-title":"Acute intraocular inflammation following intravitreal injection of bevacizumab\u2014a large cluster of cases","volume":"89","author":"Fielden","year":"2011","journal-title":"Acta Ophthalmologica"},{"key":"10.1016\/j.ajo.2011.11.023_bib9","article-title":"Update: Roche unit failed to follow safety procedures, FDA says","author":"Corbett Dooren","year":"2011","journal-title":"Wall Street Journal"},{"issue":"3","key":"10.1016\/j.ajo.2011.11.023_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ophtha.2009.07.041","article-title":"Severe intraocular inflammation after intravitreal injection of bevacizumab","volume":"117","author":"Sato","year":"2010","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2011.11.023_bib11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/IAE.0b013e3181bd2d51","article-title":"Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch","volume":"30","author":"Yamashiro","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2011.11.023_bib12","first-page":"140","article-title":"Verbl\u00fcffende Wirkung","volume":"40","author":"Neumann","year":"2008","journal-title":"Der Spiegel"},{"issue":"4","key":"10.1016\/j.ajo.2011.11.023_bib13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMc1106415","article-title":"Counterfeit bevacizumab and endophthalmitis","volume":"365","author":"Sun","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajo.2011.11.023_bib14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/eye.2009.86","article-title":"Serratia marcescens endophthalmitis associated with intravitreal injections of bevacizumab","volume":"24","author":"Lee","year":"2010","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.ajo.2011.11.023_bib15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/IAE.0b013e3181d50cea","article-title":"High-molecular-weight aggregates in repackaged bevacizumab","volume":"30","author":"Kahook","year":"2010","journal-title":"Retina"},{"issue":"2","key":"10.1016\/j.ajo.2011.11.023_bib16","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1167\/iovs.10-6431","article-title":"Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling","volume":"52","author":"Liu","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ajo.2011.11.023_bib17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/507336","article-title":"Outbreak of Serratia marcescens infections following injection of betamethasone compounded at a community pharmacy","volume":"43","author":"Civen","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"49","key":"10.1016\/j.ajo.2011.11.023_bib18","first-page":"1109","article-title":"Exophiala infection from contaminated injectable steroids prepared by a compounding pharmacy\u2014United States, July\u2013November 2002","volume":"51","year":"2002","journal-title":"MMWR Morbid Mortal Wkly Rep"},{"key":"10.1016\/j.ajo.2011.11.023_bib19","first-page":"261","article-title":"Recommended methods for compounding intravenous admixtures in hospitals","volume":"32","year":"1975","journal-title":"Am J Hosp Pharm"},{"key":"10.1016\/j.ajo.2011.11.023_bib20","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/ajhp\/57.12.1150","article-title":"ASHP guidelines on quality assurance for pharmacy-prepared sterile products","volume":"57","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ajo.2011.11.023_bib21","series-title":"The United States Pharmacopeia. 26th rev. The National Formulary","first-page":"2417","article-title":"Sterile drug products for home use (general information chapter 1206)","year":"2003"},{"key":"10.1016\/j.ajo.2011.11.023_bib22","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/ajhp\/53.21.2591","article-title":"National survey of quality assurance activities for pharmacy prepared sterile products in hospitals and home infusion facilities\u20141995","volume":"53","author":"Santell","year":"1996","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ajo.2011.11.023_bib23","series-title":"Report: limited FDA survey of compounded drug products","year":"2009"},{"key":"10.1016\/j.ajo.2011.11.023_bib24","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1093\/ajhp\/60.24.2567","article-title":"National survey of quality assurance activities for pharmacy-compounded sterile preparations","volume":"60","author":"Morris","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ajo.2011.11.023_bib25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/ajhp\/58.8.638","article-title":"Federal court strikes down compounding regulations","volume":"58","author":"Harteker","year":"2001","journal-title":"Am J Health System Pharm"},{"key":"10.1016\/j.ajo.2011.11.023_bib26","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/ajhp\/61.18.1928","article-title":"USP chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy","volume":"61","author":"Kastango","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ajo.2011.11.023_bib27","series-title":"The United States Pharmacopeia. 27th rev. The National Formulary","first-page":"2350","article-title":"Pharmaceutical compounding: sterile preparations (general information chapter 797)","year":"2004"},{"key":"10.1016\/j.ajo.2011.11.023_bib28","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1310\/hpj4111-1018","article-title":"It's Time to Clean Up <797>","volume":"41","author":"Sanborn","year":"2006","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.ajo.2011.11.023_bib29","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.2146\/ajhp050078","article-title":"I.V. admixture contamination rates: traditional practice site versus a class 1000 cleanroom","volume":"62","author":"Thomas","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.ajo.2011.11.023_bib30","first-page":"1","article-title":"Pharmaceutical compounding: sterile preparations (general information chapter 797)","year":"2008"},{"issue":"5","key":"10.1016\/j.ajo.2011.11.023_bib31","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.iae.0000225354.92444.7a","article-title":"Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing","volume":"26","author":"Bakri","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2011.11.023_bib32","series-title":"The United States Pharmacopeia. 31st rev. The National Formulary","first-page":"85","article-title":"Sterility tests (general information chapter 71)","year":"2008"},{"issue":"1","key":"10.1016\/j.ajo.2011.11.023_bib33","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1542\/peds.2005-2617","article-title":"Life-threatening sepsis caused by Burkholderia cepacia from contaminated intravenous flush solutions prepared by a compounding pharmacy in another state","volume":"118","author":"Held","year":"2006","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.ajo.2011.11.023_bib34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1086\/520664","article-title":"A multistate outbreak of Serratia marcescens bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy","volume":"45","author":"Sunenshine","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.ajo.2011.11.023_bib35","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1086\/592968","article-title":"Multistate outbreak of Pseudomonas fluorescens bloodstream infection after exposure to contaminated heparinized saline flush prepared by a compounding pharmacy","volume":"47","author":"Gershman","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ajo.2011.11.023_bib36","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3201\/eid1501.070616","article-title":"Sphingomonas paucimobilis bloodstream infections associated with contaminated intravenous fentanyl","volume":"15","author":"Maragakis","year":"2009","journal-title":"Emerg Infect Dis"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939411009196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939411009196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:03:38Z","timestamp":1757595818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939411009196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0002939411009196"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2011.11.023","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avastin Doesn't Blind People, People Blind People","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2011.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2011.11.035","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}